Reduction in Physician Reimbursement and Use of Hormone Therapy in Prostate Cancer
TLDR
The 2003 Medicare Modernization Act reduced reimbursements for AST by 64% between 2004 and 2005, but the effect of this large reduction on use of AST in prostate cancer is unknown.Abstract:
Background
Use of androgen suppression therapy (AST) in prostate cancer increased more than threefold from 1991 to 1999. The 2003 Medicare Modernization Act reduced reimbursements for AST by 64% between 2004 and 2005, but the effect of this large reduction on use of AST is unknown.read more
Citations
More filters
Journal ArticleDOI
Comparison of SEER Treatment Data With Medicare Claims
Anne-Michelle Noone,Jennifer L. Lund,Angela B. Mariotto,Kathleen A. Cronin,Timothy S. McNeel,Dennis Deapen,Joan L. Warren +6 more
TL;DR: SEER data should not generally be used for comparisons of treated and untreated individuals or to estimate the proportion of treated individuals in the population, andAugmenting SEER data with other data sources will provide the most accurate treatment information.
Journal ArticleDOI
Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer
Journal ArticleDOI
Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US.
Katherine E Mues,Alexander Liede,Jiannong Liu,James B. Wetmore,Rebecca Zaha,Brian D. Bradbury,Allan J. Collins,David T. Gilbertson +7 more
TL;DR: A summary of Medicare data is provided, including the types of data that are captured, and how they may be used in epidemiologic and health outcomes research, to highlight strengths, limitations, and key considerations when designing a study using Medicare data.
Journal ArticleDOI
Pharmaceutical policies: effects of financial incentives for prescribers
TL;DR: The effects of pharmaceutical policies using financial incentives to influence prescribers' practices on drug use, healthcare utilisation, health outcomes and costs are determined and pay for performance policies are evaluated.
References
More filters
Journal ArticleDOI
Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin
Michel Bolla,Dionisio Gonzalez,Padraig Warde,Jean Bernard Dubois,René-Olivier Mirimanoff,Guy Storme,Jacques Bernier,Abraham Kuten,Cora N. Sternberg,Thierry Gil,Laurence Collette,Marianne Pierart +11 more
TL;DR: Adjuvant treatment with goserelin, when started simultaneously with external irradiation, improves local control and survival in patients with locally advanced prostate cancer.
Journal ArticleDOI
Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer
TL;DR: GnRH agonist treatment for men with locoregional prostate cancer may be associated with an increased risk of incident diabetes and cardiovascular disease and the benefits of GnRH agonists should be weighed against these potential risks.
Journal ArticleDOI
Risk of Fracture after Androgen Deprivation for Prostate Cancer
TL;DR: Androgen-deprivation therapy for prostate cancer increases the risk of fracture and there was a statistically significant relation between the number of doses of gonadotropin-releasing hormone received during the 12 months after diagnosis and the subsequent risk of fractures.
Journal ArticleDOI
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
Ian M. Thompson,James Brantley Thrasher,Gunnar Aus,Arthur L. Burnett,Edith D. Canby-Hagino,Michael S. Cookson,Anthony V. D'Amico,Roger Dmochowski,David T. Eton,Jeffrey D. Forman,S. Larry Goldenberg,Javier Hernandez,Celestia S. Higano,Stephen R. Kraus,Judd W. Moul,Catherine M. Tangen +15 more
TL;DR: The Prostate Cancer Clinical Guideline Update Panel is a free resource for clinicians and researchers to assess the need for and ability to evaluate the risks and benefits of utilizing the PSA in men and women diagnosed with prostate cancer.
Journal ArticleDOI
Uncertainty and the welfare economics of medical care
TL;DR: This chapter focuses on the way in which the operation of the medical-care industry and the efficacy with which it satisfies the needs of society differ from a norm.